Growth Hormone-Releasing Hormone (GHRH) is a hypothalamic peptide hormone that plays a central role in the neuroendocrine regulation of growth hormone (GH) secretion from the anterior pituitary gland. It was first isolated and characterized from human pancreatic tumors causing acromegaly, and its endogenous human form consists of 44 amino acids, though shorter active fragments like the 1-29 and 1-40 sequences are common. GHRH is a key component of the hypothalamic-pituitary-somatotropic axis, acting as the primary stimulatory signal for pulsatile GH release. Its discovery was pivotal in understanding the regulation of somatic growth, metabolism, and body composition. Research on GHRH and its analogs has significant implications for conditions involving GH deficiency, aging, and metabolic disorders.
Quick Facts
| Also Known As | GHRH, Growth Hormone-Releasing Factor, GRF, Somatocrinin, hpGRF |
|---|---|
| Sequence | H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2 |
| Molecular Formula | C215H366N72O67S (for GHRH(1-44)-NH2). Formula varies by specific fragment and C-terminal amidation. |
| Molecular Weight | Approximately 5040 Da (for GHRH(1-44)-NH2). Molecular weight varies by fragment (e.g., GHRH(1-29) is ~3350 Da). |
Research Parameters
| Half-Life | Short, approximately 5-10 minutes in plasma for the native peptide. Synthetic analogs like Tesamorelin (modified for DPP-IV resistance) have a longer half-life of ~30-40 minutes. |
|---|---|
| Stability | Lyophilized powder is stable for at least 24 months when stored at -20°C, protected from light and moisture. After reconstitution in bacteriostatic water or sterile buffer, the solution should be stored at 2-8°C. Stability after reconstitution is typically cited as 14-28 days at 4°C, but researchers should refer to specific manufacturer data for the product used. |
| Solubility | Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Water for Injection. Acetic acid or saline buffers (pH ~5.5) are also used in research settings to enhance solubility and stability. |
| Vial Size | 2 mg |
| Storage (Lyophilized) | -20°C or below, in a sealed container, protected from light and moisture. For long-term storage, desiccant is recommended. |
| Storage (Reconstituted) | 2-8°C (refrigerated, not frozen). Should be used within the timeframe specified by the research product manufacturer, typically within 14-28 days. |
| Typical Research Dose | Research doses vary widely: 1-2 mcg/kg for physiological studies, 100-200 mcg for diagnostic tests, and 1000-2000 mcg (1-2 mg) per day for clinical trial protocols with specific analogs. |
| Cycle Parameters | Research protocols vary. For studies on aging or body composition, a common protocol involves daily subcutaneous injection (often at bedtime) for periods ranging from 12 weeks to 6 months. Many studies do not incorporate an 'off' cycle, as the treatment period is defined by the study duration. |
| Amino Acid Count | 31 |
Mechanism of Action
GHRH exerts its effects primarily by binding to the GHRH receptor (GHRHR), a G-protein coupled receptor (GPCR) expressed on somatotroph cells in the anterior pituitary. This binding initiates a well-characterized intracellular signaling cascade.
GHRHR Activation and cAMP/PKA Pathway: Binding of GHRH to its receptor activates the stimulatory G-protein (Gs), which in turn activates adenylate cyclase. This enzyme converts ATP to cyclic AMP (cAMP), leading to the activation of protein kinase A (PKA). PKA phosphorylates key transcription factors, most notably cAMP response element-binding protein (CREB), which translocates to the nucleus and promotes the transcription of the GH gene (GH1) and the gene for the pituitary-specific transcription factor Pit-1.
Calcium Influx and GH Exocytosis: The cAMP/PKA pathway also modulates voltage-gated calcium channels, leading to an influx of extracellular calcium. The rise in intracellular calcium concentration, often in a pulsatile manner synchronized with GHRH pulses, triggers the exocytosis of pre-synthesized GH secretory granules into the bloodstream.
Interaction with Somatostatin: The secretory response to GHRH is critically modulated by the inhibitory hormone somatostatin (SRIF). GHRH and somatostatin exhibit a reciprocal relationship; troughs in somatostatin tone allow GHRH pulses to be fully effective. GHRH may also indirectly influence somatostatinergic neuron activity via feedback loops involving GH and insulin-like growth factor 1 (IGF-1).
Research Applications
Growth Hormone Deficiency (GHD) Research: GHRH has been extensively studied as a diagnostic tool and a potential therapeutic agent for both childhood-onset and adult-onset GHRH-responsive GH deficiency. Research protocols use GHRH stimulation tests to assess pituitary reserve. Studies in elderly subjects with relative GH decline (somatopause) have shown that GHRH administration can restore more youthful pulsatile GH secretion patterns, improving body composition parameters.
Metabolic and Body Composition Research: Investigations focus on GHRH's ability to promote lipolysis and reduce visceral adiposity. By stimulating GH release, GHRH influences metabolic pathways that increase fatty acid oxidation and improve insulin sensitivity in certain contexts. Research in animal models and human subjects examines its role in reversing some metabolic alterations associated with aging and obesity.
Cognitive and Neuroprotective Research: Preclinical studies suggest GHRH and its analogs may have direct effects on the central nervous system, independent of GH. Research areas include potential benefits for cognitive function, sleep quality, and neuroprotection, possibly mediated through GHRH receptors expressed in the hippocampus and other brain regions. This is an emerging area of investigation.
Aging Research (Gerontology): As a physiological regulator of the somatotropic axis, GHRH is a key molecule in research on endocrine aging. Studies explore whether restoring youthful GHRH activity can counteract age-related declines in muscle mass, bone density, skin thickness, and immune function, with the goal of promoting 'healthspan'.
Safety & Side Effects
In controlled research settings, GHRH administration is generally associated with fewer side effects compared to direct GH administration, as it preserves the pulsatile, feedback-regulated secretion of endogenous GH. Reported side effects from clinical trials are often mild and transient. These may include injection site reactions (erythema, pruritus, pain), flushing, headache, and dizziness. Due to the increase in GH and subsequently IGF-1, theoretical concerns similar to those for GH excess exist, including potential for fluid retention, arthralgia, myalgia, carpal tunnel syndrome, and insulin resistance, though these are less commonly observed with GHRH than with exogenous GH. Anecdotal reports from non-clinical use are not systematically documented in the literature. Long-term safety data beyond controlled trial periods are limited.
Dosage Information
This information is derived solely from published scientific research protocols and is for research purposes only. Typical research doses vary significantly based on the specific GHRH analog (e.g., GHRH(1-29), Tesamorelin), study objectives, and subject population.
For diagnostic testing (GHRH stimulation test), a single intravenous bolus of 1 mcg/kg or 100 mcg is commonly used. For longer-term research studies in adults (e.g., aging or HIV-associated lipodystrophy), subcutaneous injections are typical. Doses often range from 1-2 mg per day for analogs like Tesamorelin. In research on age-related GH decline, doses such as 1-2 mcg/kg body weight administered subcutaneously at bedtime have been used to mimic physiological nocturnal pulses. Frequency is typically daily, and study durations in clinical trials have ranged from several weeks to 12 months or more.
References
Guillemin, R., Brazeau, P., Böhlen, P., Esch, F., Ling, N., & Wehrenberg, W.B. (1982). Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science, 218(4572), 585-587.
Thorner, M.O., Vance, M.L., Hartman, M.L., et al. (1990). Physiological role of somatostatin on growth hormone regulation in humans. Metabolism, 39(9 Suppl 2), 40-42.
Corpas, E., Harman, S.M., & Blackman, M.R. (1993). Human growth hormone and human aging. Endocrine Reviews, 14(1), 20-39.
Fryburg, D.A., & Gelfand, R.A. (1991). Growth hormone releasing hormone (GHRH) administration in fasting humans stimulates lipid oxidation but not protein catabolism. Journal of Clinical Endocrinology & Metabolism, 73(6), 1203-1208.
Veldhuis, J.D., Iranmanesh, A., Weltman, A. (1997). Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans. Endocrine, 7(1), 41-48.
Mulligan, K., Khatami, H., Schwarz, J.M., et al. (2009). The effects of recombinant human growth hormone on liver and adipose tissue in fasted humans: a randomized controlled study. Journal of Clinical Endocrinology & Metabolism, 94(8), 2828-2835. (Related to GHRH effects via GH).
Stanley, T.L., Feldpausch, M.N., Oh, J., et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA, 312(4), 380-389.